Accretion Nutraveda Ltd. (ANL) Share Price Within 2% of 52-Week High

Accretion Nutraveda Ltd. shares traded at Rs 300, placing the stock within 2% of its 52-week high. The company’s market capitalisation stands at Rs 207.06 crore.

Accretion Nutraveda Ltd. Share Price was at Rs 300 at the time this Univest article was prepared, putting the stock within 2% of its 52-week high and valuing the company at a market capitalisation of Rs 207.06 crore. For market participants screening for stocks close to their one-year peaks, that is a notable price-positioning event because it places Accretion Nutraveda Ltd. on the radar without implying a breakout or a fresh record.

The verified data confirms that Accretion Nutraveda Ltd. Share Price qualified on the Univest screener at Rs 300 under the near-52-week-high condition. In practical terms, this means investors are watching a Healthcare stock from the Pharmaceuticals & Drugs industry that is trading close to its yearly high while also carrying a relatively rich valuation profile on some metrics and strong profitability on others.

That combination matters. A stock near its one-year high often attracts attention from traders, momentum followers and long-term investors who want to test whether price strength is being supported by financial performance, industry positioning and comparative valuations. Based on the supplied dataset, Univest can confirm the price event and the company’s financial context, but the data does not establish a company-specific catalyst for today’s attention.

Accretion Nutraveda Ltd. Share Price Today: Within 2% of 52-Week High

Metric	Value
LTP at 2% Qualification	Rs 300
Market Capitalisation	Rs 207.06 crore
52-Week High Position	Trading within 2% of its 52-week high

Accretion Nutraveda Ltd. (ANL) traded at Rs 300. Reported volume was 7,000.

Accretion Nutraveda Ltd. Share Price Today stood at Rs 300 when the stock met the Univest screener condition for trading within 2% of its 52-week high. The event-qualified last traded price was also Rs 300, which gives a clean reference point for this stock analysis. The significance of that placement is not that the share has crossed any specific threshold beyond what the screener confirms, but that it is now trading close enough to its one-year peak to draw fresh market attention.

When a stock moves into this zone, investors usually read it as evidence that demand has remained resilient over a broader period. In the case of Accretion Nutraveda Ltd. Share Price, the market is assigning a current equity value of Rs 207.06 crore to the business. That places the company above the industry median market capitalisation of Rs 137.36 crore, though still below the same-industry average of Rs 483.51 crore. So this is not a large-cap move driven by size alone; it is a smaller Healthcare counter being tracked for its price positioning and its underlying metrics.

The Univest screener identification matters because proximity to a 52-week high tends to focus attention on whether valuation, profitability and peer comparison support the current market interest. For Accretion Nutraveda Ltd. Share Price, the next logical step is to examine whether the company’s financial profile justifies this visibility.

Accretion Nutraveda Ltd. (ANL) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 207.06 crore
P/E Ratio	40.85x
P/B Ratio	6.56x
ROE	106.65%
ROCE	21.4%
EPS	Rs 7
Book Value Per Share	Rs 43.6
Dividend Yield	0%

Accretion Nutraveda Ltd. was valued at a P/E ratio of 40.85x, a P/B ratio of 6.56x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 106.65% and ROCE of 21.4%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 7, book value per share of Rs 43.6, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	40.85x
Benchmark Median P/E	19.11x
Benchmark Average P/E	30.35x
Benchmark P/E Range	0x to 361.02x
Company P/B Ratio	6.56x
Benchmark Median P/B	1.75x
Company ROE	106.65%
Benchmark Median ROE	9.87%
Company ROCE	21.4%
Benchmark Median ROCE	12.57%
Company Market Capitalisation	Rs 207.06 crore
Benchmark Median Market Cap	Rs 137.36 crore

Accretion Nutraveda Ltd. (ANL) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Accretion Nutraveda Ltd. (ANL) has a P/E ratio of 40.85x, which is above the benchmark median of 19.11x, a difference of +113.76%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Accretion Nutraveda Ltd. (ANL) has a ROE of 106.65%, which is above the benchmark median of 9.87%, a difference of +980.55%. Accretion Nutraveda Ltd. (ANL) has a ROCE of 21.4%, which is above the benchmark median of 12.57%, a difference of +70.25%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Coral Laboratories Ltd.	CORALAB	205.3	10.69	0.98	10.74	13.35
Accretion Pharmaceuticals Ltd.	ACCPL-ST	211.76	21.9	4.06	27.18	12.62
Gujarat Inject (Kerala) Ltd.	GUJINJEC	185.46	61.96	14.17	0	0
Brooks Laboratories Ltd.	BROOKS-BE	185.14	14.01	1.49	-23.18	-18.72
BIO MEDICA LABORATORIES L	BMLL-SM	181.52	15.56	2.93	13.67	10.17

Accretion Nutraveda Ltd. (ANL) has a P/E ratio of 40.85x compared with the displayed peer median of 15.56x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 106.65% compares with a peer median of 10.74% across the companies shown in the table. ROCE stood at 21.4% versus the displayed peer median of 10.17%, providing a capital-efficiency comparison. Accretion Nutraveda Ltd. (ANL) has a market capitalisation of Rs 207.06 crore. Among the 5 peers shown, 1 have a larger market capitalisation.

Why Investors Are Watching Accretion Nutraveda Ltd.

• Accretion Nutraveda Ltd. Share Price is at Rs 300 and the stock is trading within 2% of its 52-week high on the Univest screener.
• The company’s market capitalisation of Rs 207.06 crore is above the same-industry median of Rs 137.36 crore, giving it visible scale within smaller listed peers.
• Valuation is elevated, with P/E at 40.85 and P/B at 6.56, both above same-industry medians and averages.
• Profitability is strong on supplied numbers, with ROE of 106.65% and ROCE of 21.4%, both above industry benchmark medians.
• EPS of 7 and book value of Rs 43.6 provide additional context behind the current price, while dividend yield stands at 0.
• RSI at 57.73 places momentum in a broadly neutral-to-firm zone rather than an overheated one on the supplied reading.
• Peer data shows the stock trades at a premium to several similar-sized companies, but also carries stronger return ratios than many of them.

About Accretion Nutraveda Ltd.

Accretion Nutraveda Ltd. is classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. That positioning places the company within a listed universe where investors often compare valuation multiples, return ratios and market capitalisation against a broad set of specialised drug and healthcare businesses.

Based on the supplied company context, the market currently values Accretion Nutraveda Ltd. at Rs 207.06 crore, which is above the median market capitalisation for its same-industry comparison group. This suggests the company occupies a visible, though not dominant, place among smaller listed pharmaceutical and drug-related names.

For investors following Accretion Nutraveda Ltd. Share Price, the company profile is relevant mainly because its industry sits inside a highly comparable listed ecosystem. That allows closer benchmarking on P/E, P/B, ROE and ROCE than in many other sectors. In this case, the stock is being monitored not only because it is close to its yearly high, but also because its profitability ratios stand out against a large same-industry sample. On Univest, that makes the company a useful case study in how price strength, premium valuation and strong return metrics can appear together in a Healthcare stock.

Track Accretion Nutraveda Ltd. Share Price on Univest

Use Accretion Nutraveda Ltd. (ANL) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Investors tracking Accretion Nutraveda Ltd. Share Price can use Univest to monitor live share price moves, 52-week levels, valuation ratios, profitability indicators, peer comparisons and broader market context in one place. For a stock trading within 2% of its 52-week high, those tools are useful because they help separate simple price visibility from deeper financial context.

On Univest, users can follow Accretion Nutraveda Ltd. Share Price Today alongside metrics such as P/E, P/B, ROE, ROCE, EPS, book value and market capitalisation. They can also compare the stock with other Healthcare and Pharmaceuticals & Drugs companies to understand how current pricing stacks up against sector medians, averages and listed peers.

Frequently Asked Questions

What is Accretion Nutraveda Ltd. Share Price today?

Ans. Accretion Nutraveda Ltd. Share Price was Rs 300 when the stock qualified on the Univest screener. At that level, the company carried a market capitalisation of Rs 207.06 crore and was trading within 2% of its 52-week high.

Why is Accretion Nutraveda Ltd. Share Price in focus today?

Ans. Accretion Nutraveda Ltd. Share Price is in focus because the verified screener data shows the stock trading within 2% of its 52-week high. That places it near its one-year peak and naturally draws attention to valuation and profitability.

Is Accretion Nutraveda Ltd. Share Price expensive compared with its industry?

Ans. On supplied numbers, Accretion Nutraveda Ltd. Share Price reflects a P/E of 40.85 versus the same-industry median of 19.11 and average of 30.35. Its P/B of 6.56 is also above the median 1.75 and average 2.28.

How strong are the fundamentals behind Accretion Nutraveda Ltd. Share Price?

Ans. The supplied fundamentals show ROE of 106.65%, ROCE of 21.4%, EPS of 7 and book value of Rs 43.6. These figures indicate strong reported return metrics, even as the market currently assigns premium valuation multiples.

What does the dividend data say about Accretion Nutraveda Ltd. Share Price?

Ans. The dividend yield for Accretion Nutraveda Ltd. is 0 in the supplied dataset. That means the current investment case, based on available figures, is centred on price positioning, valuation and profitability rather than historical yield support.

How does Accretion Nutraveda Ltd. Share Price compare with peers?

Ans. Accretion Nutraveda Ltd. trades at a higher P/E than Coral Laboratories, Accretion Pharmaceuticals, Brooks Laboratories and BIO MEDICA LABORATORIES L, but its ROE of 106.65% and ROCE of 21.4% are stronger than several similarly sized peers.

What does sector data indicate for Accretion Nutraveda Ltd. Share Price?

Ans. Sector data uses a same-industry benchmark covering 138 Pharmaceuticals & Drugs companies. Accretion Nutraveda Ltd. sits above benchmark medians on P/E, P/B, ROE and ROCE, while its market capitalisation of Rs 207.06 crore exceeds the median Rs 137.36 crore.